Senti Biosciences Holdings (SNTI) Cash & Equivalents (2021 - 2025)

Senti Biosciences Holdings' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $16.4 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 66.05% year-over-year to $16.4 million; the TTM figure through Dec 2025 stood at $16.4 million (down 66.05% YoY), while the FY2025 annual figure was $16.4 million, down 66.05% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $16.4 million, up from $12.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $139.8 million in Q2 2022, with the low at $10.5 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $36.8 million (2023), against an average of $46.8 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 68.55% in 2022, then plunged 73.71% in 2023.
• Senti Biosciences Holdings' Cash & Equivalents stood at $56.0 million in 2021, then climbed by 2.83% to $57.6 million in 2022, then tumbled by 37.65% to $35.9 million in 2023, then surged by 34.44% to $48.3 million in 2024, then tumbled by 66.05% to $16.4 million in 2025.
• Business Quant data shows SNTI's Cash & Equivalents at $16.4 million in Q4 2025, $12.2 million in Q3 2025, and $21.6 million in Q2 2025.